Details

Autor(en) / Beteiligte

• Quiroga, Borja
• Soler, María José
• Ortiz, Alberto
• Vaquera, Shaira Martínez
• Mantecón, Carlos Jesús Jarava
• Useche, Gustavo
• Márquez, María Gabriela Sánchez
• Carnerero, Manuel
• Rodríguez, María Teresa Jaldo
• Ramos, Patricia Muñoz
• Millán, Juan Carlos Ruiz San
• Toapanta, Nestor
• Gracia-Iguacel, Carolina
• Cervera, María Cinta Aguilar
• Lara, Noelia Balibrea
• Leyva, Alba
• Rojas, José
• Gansevoort, Ron T
• de Sequera, Patricia

Titel

Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study

Ist Teil von

• Nephrology, dialysis, transplantation, 2022-09, Vol.37 (10), p.1868-1878

Ort / Verlag

England: Oxford University Press

Erscheinungsjahr

2022

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Chronic kidney disease (CKD) patients are at high-risk for severe Covid-19. The multicentric, observational and prospective SENCOVAC study aims to describe the humoral response and safety of SARS-CoV-2 vaccines in CKD patients. Safety and immediate humoral response results are reported here. Four cohorts of patients were included: kidney transplant (KT) recipients, haemodialysis (HD), peritoneal dialysis (PD) and non-dialysis CKD patients from 50 Spanish centres. Adverse events after vaccine doses were recorded. At baseline and on day 28 after the last vaccine dose, anti-Spike antibodies were measured and compared between cohorts. Factors associated with development of anti-Spike antibodies were analyzed. 1746 participants were recruited: 1116 HD, 171 PD, 176 non-dialysis CKD patients and 283 KT recipients. Most patients (98%) received mRNA vaccines. At least one vaccine reaction developed after the first dose in 763 (53.5%) and after the second dose in 741 (54.5%) of patients. Anti-Spike antibodies were measured in the first 301 patients. At 28 days, 95% of patients had developed antibodies: 79% of KT, 98% of HD, 99% of PD and 100% of non-dialysis CKD patients (p<0.001). In a multivariate adjusted analysis, absence of an antibody response was independently associated to KT (OR 20.56, p = 0.001) and to BNT162b2 vaccine (OR 6.03, p = 0.023). The rate of anti-Spike antibody development after vaccination in KT patients was low but in other CKD patients it approached 100%; suggesting that KT patients require persistent isolation measures and booster doses of a Covid-19 vaccine. Potential differences between Covid-19 vaccines should be explored in prospective controlled studies.